First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Public ClinicalTrials.gov record NCT05216432. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT05216432
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Enrollment
- 930 participants
Conditions and interventions
Conditions
Interventions
- Fulvestrant Drug
- PF-07220060 100mg Drug
- PF-07220060 300 mg Drug
- Palbociclib 125mg Drug
- RLY-2608 Drug
- Ribociclib 400mg Drug
- Ribociclib 600mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2021
- Primary completion
- Apr 29, 2027
- Completion
- Apr 29, 2027
- Last update posted
- Sep 21, 2025
2021 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | Recruiting |
| University of California-San Diego | San Diego | California | 90293 | Recruiting |
| HealthONE | Denver | Colorado | 80218 | Recruiting |
| Yale University | New Haven | Connecticut | 06510 | Recruiting |
| Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| Boca Raton Clinical Research (BRCR) Global | Plantation | Florida | 33322 | Withdrawn |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Recruiting |
| Community Health Network | Indianapolis | Indiana | 46250 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Washington University School of Medicine St. Louis | St Louis | Missouri | 63110 | Recruiting |
| Renown Regional Medical Center | Reno | Nevada | 89502 | Recruiting |
| Rutgers University | New Brunswick | New Jersey | 08901 | Recruiting |
| NYU Langone | New York | New York | 10016 | Recruiting |
| Columbia University Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | Recruiting |
| Memorial Sloan Kettering | New York | New York | 10065 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | Recruiting |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| University of Utah- Huntsman Cancer Center | Salt Lake City | Utah | 84112 | Recruiting |
| Inova Schar Cancer Center | Fairfax | Virginia | 22031 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22301 | Recruiting |
| UW Carbone Cancer Center | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05216432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05216432 live on ClinicalTrials.gov.